Key facts
- This page summarizes Timothy Keutzer's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2026, 06:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Sale
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 2, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F2
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Footnote F3
The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.